Drug Profile

TBA 7371

Alternative Names: TBA-7371

Latest Information Update: 23 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca; Global Alliance for TB Drug Development
Developer Bill & Melinda Gates Medical Research Institute; Global Alliance for TB Drug Development
Class Antituberculars; Indoles
Mechanism of Action DprE1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Tuberculosis

Most Recent Events

23 Feb 2022 TBA 7371 is still in phase II trials for Tuberculosis in USA
16 Jan 2020 Phase-II clinical trials in Tuberculosis (Treatment-naive) in South Africa (PO) (NCT04176250)
25 Nov 2019 Bill & Melinda Gates Medical Research Institute plans a phase II trial for Pulmonary tuberculosis (Treatment-naïve) in South Africa (PO, suspension) (NCT04176250)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com